

President & CEO

Hiroshi Tomiyama, Ph.D.

Area of Expertise

Medicinal Chemistry, Pharmaceutical Engineering, Accounting & Financial Analysis, Pharmaceutical Business

Qualifications

1997: Ph.D. in Pharmaceutical Science, The University of Tokyo

1992: Bachelor of Science in Pharmacy, Tokyo University of Pharmacy & Life Sciences, Pharmacist

1990: Radiation Protection Officer in sophomore year at university

Work Experiences

2017-2019: (Concurrent) Part-time Lecturer, Medicinal Chemistry, Graduate School & Faculty of Pharmaceutical Sciences, Chiba University, Japan

2014 -present: President & CEO at Kotobuki Pharma

2007: Executive Director

2000: Joined Kotobuki Pharma as a research scientist

1997-1999: Postdoctoral Researcher under the supervision of Professor Robert J. Linhardt, Division of Medicinal and Natural Products Chemistry (MNPC), College of Pharmacy, The University of Iowa, USA

Program: The synthesis of catabolically stable C-glycoside analogue of cancer carbohydrate antigen toward cancer vaccine development.

Awards

Medicinal Chemistry;

2015: Breakthrough Award, Division of Medicinal Chemistry, Pharmaceutical Society of Japan

Title: Discovery of ipragliflozin (Suglat®): A potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Pharmaceutical Engineering;

2022: The 21st Century research grants, Nagano Pharmaceutical Association

Title: The development of easy to split with fingers and easy to swallow of “KAWARA” Orally Disintegrating tablets®

Publications : ScholarGPS® ID: 78182769548147 (Affiliation: Kotobuki Pharma)

Books

2024: “Modern Natural Product Synthesis: Overcoming Difficulties”, Foreword, Springer

2008: “Chemical Glycobiology”; Synthesis and Evaluation of Anticancer Vaccine Candidates, C-Glycoside Analogs of STn and PSA, American Chemical Society Symposium Series, 990, 216-238

Invited Speaker (International)

2015: MRC Symposium, Collage of Pharmacy, Seoul National University, Korea

Title: “A key turning point of SGLT2 Inhibitors; From O-glycoside to C-glycoside”

2011: Kunming Institute of Botany seminar, Kunming Institute of Botany, Chinese Academy of Sciences, China

Title: “Development of KT6-971: A C-glycoside of NPC1L1 transporter inhibitor”

2010: 239th American Chemical Society National Meeting, Division of Medicinal Chemistry, San Francisco, USA

Title: “Development of KT6-971: A C-glycoside of NPC1L1 transporter inhibitor”

2005: The 1st Symposium on Glycosaminoglycans, Natural Products Research Institute, Collage of Pharmacy, Seoul National University, Korea, Title: “The recent research of active tumor immunotherapy”

Pharmaceutical Engineering Patents granted in Japan